Showing results (1-10 of 39) with videos related to
Sort By:
Pageof 4
BMC Public Health|March 2, 2011
A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges aheadCatherine A A Beauchemin, Andreas HandelBMC Public Health|March 2, 2011
Exploring the effect of biological delays in kinetic models of influenza within a host or cell cultureBenjamin P Holder, Catherine A A BeaucheminPlos One|July 13, 2017
Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanismsHana M Dobrovolny, Catherine A A BeaucheminScientific Reports|February 17, 2017
Duration of SHIV production by infected cells is not exponentially distributed: Implications for estimates of infection parameters and antiviral efficacyCatherine A A Beauchemin, Tomoyuki Miura, Shingo IwamiScientific Reports|January 10, 2017
The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patientsJohn Palmer, Hana M Dobrovolny, Catherine A A BeaucheminJournal of the Royal Society, Interface|November 25, 2016
(In)validating experimentally derived knowledge about influenza A defective interfering particlesLaura E Liao, Shingo Iwami, Catherine A A BeaucheminInformation Sciences|February 18, 2010
Agent-based modeling of host-pathogen systems: The successes and challengesAmy L Bauer, Catherine A A Beauchemin, Alan S PerelsonErgonomics|January 12, 2018
Modelling endurance and resumption times for repetitive one-hand pushingLinda M Rose, Catherine A A Beauchemin, W Patrick NeumannPlos Computational Biology|February 4, 2022
Correction: A mathematical model describing the localization and spread of influenza A virus infection within the human respiratory tractChristian Quirouette, Nada P Younis, Micaela B Reddy, et al.Plos One|August 25, 2017
Exploring virus release as a bottleneck for the spread of influenza A virus infection in vitro and the implications for antiviral therapy with neuraminidase inhibitorsLaura E Liao, Szymon Kowal, Daniel A Cardenas, et al.Pageof 4